Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole vs Other PPIs in GERD Treatment Failure
NCT00272701Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of patients free from heartburn. Started Dec 2005; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00272701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272701.